Alnylam Pharmaceuticals EBITDA 2010-2024 | ALNY
Alnylam Pharmaceuticals EBITDA for the quarter ending December 31, 2024 was $-0.126B, a 7.17% decline year-over-year.
- Alnylam Pharmaceuticals 2024 EBITDA was -0.12B, a 47.3% decline from 2023.
- Alnylam Pharmaceuticals 2023 EBITDA was -0.228B, a 69.2% decline from 2022.
- Alnylam Pharmaceuticals 2022 EBITDA was -0.741B, a 19.65% increase from 2021.
EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.